261 related articles for article (PubMed ID: 26030065)
1. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.
Talekar MK; Allen JE; Dicker DT; El-Deiry WS
Cell Cycle; 2015 Aug; 14(15):2422-8. PubMed ID: 26030065
[TBL] [Abstract][Full Text] [Related]
2. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.
Allen JE; Krigsfeld G; Patel L; Mayes PA; Dicker DT; Wu GS; El-Deiry WS
Mol Cancer; 2015 May; 14():99. PubMed ID: 25927855
[TBL] [Abstract][Full Text] [Related]
3. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
Prabhu VV; Allen JE; Dicker DT; El-Deiry WS
Cancer Res; 2015 Apr; 75(7):1423-32. PubMed ID: 25712124
[TBL] [Abstract][Full Text] [Related]
4. New kid on the block: ONC201 in NHL.
Wang M
Cell Cycle; 2015; 14(22):3526. PubMed ID: 26102059
[No Abstract] [Full Text] [Related]
5. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
Prabhu VV; Talekar MK; Lulla AR; Kline CLB; Zhou L; Hall J; Van den Heuvel APJ; Dicker DT; Babar J; Grupp SA; Garnett MJ; McDermott U; Benes CH; Pu JJ; Claxton DF; Khan N; Oster W; Allen JE; El-Deiry WS
Cell Cycle; 2018; 17(4):468-478. PubMed ID: 29157092
[TBL] [Abstract][Full Text] [Related]
6. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
[TBL] [Abstract][Full Text] [Related]
7. ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.
Ralff MD; Kline CLB; Küçükkase OC; Wagner J; Lim B; Dicker DT; Prabhu VV; Oster W; El-Deiry WS
Mol Cancer Ther; 2017 Jul; 16(7):1290-1298. PubMed ID: 28424227
[TBL] [Abstract][Full Text] [Related]
8. First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent.
Allen JE; Crowder RN; El-Deiry WS
PLoS One; 2015; 10(11):e0143082. PubMed ID: 26580220
[TBL] [Abstract][Full Text] [Related]
9. Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo.
Jhaveri AV; Zhou L; Ralff MD; Lee YS; Navaraj A; Carneiro BA; Safran H; Prabhu VV; Ross EA; Lee S; El-Deiry WS
Cancer Biol Ther; 2021 Dec; 22(10-12):607-618. PubMed ID: 34856854
[TBL] [Abstract][Full Text] [Related]
10. Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer
Ray JE; Ralff MD; Jhaveri A; Zhou L; Dicker DT; Ross EA; El-Deiry WS
Cancer Biol Ther; 2021 Dec; 22(10-12):554-563. PubMed ID: 34696710
[TBL] [Abstract][Full Text] [Related]
11. Small Molecular TRAIL Inducer ONC201 Induces Death in Lung Cancer Cells: A Preclinical Study.
Feng Y; Zhou J; Li Z; Jiang Y; Zhou Y
PLoS One; 2016; 11(9):e0162133. PubMed ID: 27626799
[TBL] [Abstract][Full Text] [Related]
12. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.
Daniel D; Yang B; Lawrence DA; Totpal K; Balter I; Lee WP; Gogineni A; Cole MJ; Yee SF; Ross S; Ashkenazi A
Blood; 2007 Dec; 110(12):4037-46. PubMed ID: 17724141
[TBL] [Abstract][Full Text] [Related]
13. ONC201/TIC10 plus TLY012 anti-cancer effects via apoptosis inhibitor downregulation, stimulation of integrated stress response and death receptor DR5 in gastric adenocarcinoma.
Parker CS; Zhou L; Prabhu VV; Lee S; Miner TJ; Ross EA; El-Deiry WS
Am J Cancer Res; 2023; 13(12):6290-6312. PubMed ID: 38187068
[TBL] [Abstract][Full Text] [Related]
14. The preclinical evaluation of TIC10/ONC201 as an anti-pancreatic cancer agent.
Zhang Q; Wang H; Ran L; Zhang Z; Jiang R
Biochem Biophys Res Commun; 2016 Aug; 476(4):260-266. PubMed ID: 27233611
[TBL] [Abstract][Full Text] [Related]
15. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
Prabhu VV; Morrow S; Rahman Kawakibi A; Zhou L; Ralff M; Ray J; Jhaveri A; Ferrarini I; Lee Y; Parker C; Zhang Y; Borsuk R; Chang WI; Honeyman JN; Tavora F; Carneiro B; Raufi A; Huntington K; Carlsen L; Louie A; Safran H; Seyhan AA; Tarapore RS; Schalop L; Stogniew M; Allen JE; Oster W; El-Deiry WS
Neoplasia; 2020 Dec; 22(12):725-744. PubMed ID: 33142238
[TBL] [Abstract][Full Text] [Related]
16. Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy.
Wang J; Wang H; Wang LY; Cai D; Duan Z; Zhang Y; Chen P; Zou JX; Xu J; Chen X; Kung HJ; Chen HW
Cell Death Differ; 2016 Nov; 23(11):1886-1896. PubMed ID: 27612013
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.
Wagner J; Kline CL; Ralff MD; Lev A; Lulla A; Zhou L; Olson GL; Nallaganchu BR; Benes CH; Allen JE; Prabhu VV; Stogniew M; Oster W; El-Deiry WS
Cell Cycle; 2017 Oct; 16(19):1790-1799. PubMed ID: 28489985
[TBL] [Abstract][Full Text] [Related]
18. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment.
Wagner J; Kline CL; Zhou L; Campbell KS; MacFarlane AW; Olszanski AJ; Cai KQ; Hensley HH; Ross EA; Ralff MD; Zloza A; Chesson CB; Newman JH; Kaufman H; Bertino J; Stein M; El-Deiry WS
J Clin Invest; 2018 Jun; 128(6):2325-2338. PubMed ID: 29533922
[TBL] [Abstract][Full Text] [Related]
19. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.
Prabhu VV; Lulla AR; Madhukar NS; Ralff MD; Zhao D; Kline CLB; Van den Heuvel APJ; Lev A; Garnett MJ; McDermott U; Benes CH; Batchelor TT; Chi AS; Elemento O; Allen JE; El-Deiry WS
PLoS One; 2017; 12(8):e0180541. PubMed ID: 28767654
[TBL] [Abstract][Full Text] [Related]
20. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10.
Allen JE; Prabhu VV; Talekar M; van den Heuvel AP; Lim B; Dicker DT; Fritz JL; Beck A; El-Deiry WS
Cancer Res; 2015 Apr; 75(8):1668-74. PubMed ID: 25681273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
